ToDx develops molecular diagnostic kits that deliver hospital-grade testing accuracy at the point of need, including in-home settings. Their initial product provides rapid, reliable detection for sexually transmitted infections using simple sample collection methods. This platform aims to accelerate diagnosis, improve patient access, and reduce the cost associated with traditional laboratory testing.
Funding
Funding not disclosed
Founders
Product
Problem
Significant barriers such as inconvenience, cost, and stigma prevent widespread testing for infectious diseases, leading to many infections going undiagnosed and untreated. Current diagnostic methods often require specialized laboratory equipment and trained personnel, limiting accessibility and delaying timely intervention.
Solution
ToDx provides a decentralized molecular diagnostic platform that delivers lab-quality accuracy for infectious diseases within 60 minutes at the point of need. The platform utilizes a single-use kit that requires only a smartphone for result interpretation, enabling testing in clinical settings or at home without specialized equipment or electrical outlets. This approach aims to improve detection rates, streamline patient care pathways, and enhance overall health outcomes by making diagnostics more accessible and convenient. The underlying technology leverages established molecular methods to ensure high sensitivity and specificity, with built-in safeguards to mitigate sampling and handling errors.
Target Audience
The primary target audience includes virtual care providers, retail clinics, walk-in centers, physician offices, and patients seeking convenient and accurate diagnostic testing.
Features
- Single-use molecular diagnostic kit for rapid detection of Chlamydia, Gonorrhea, and Trichomonas within 60 minutes.
- Smartphone-based result interpretation, eliminating the need for separate diagnostic devices or laboratory infrastructure.
- Employs molecular methods comparable to top-tier laboratory systems to achieve high sensitivity and specificity.
- Integrated error-detection mechanisms to prevent false results stemming from sampling or handling inaccuracies.
- Scalable technology platform adaptable for future applications, including respiratory infections, UTIs, and broader syndromic panels.
- Over 50% cost reduction per test compared to existing point-of-care and mail-in testing solutions.